This advisory introduces readers to digital therapeutics (DTx) and the benefits of their use in behavioral health. It describes the research, regulatory, and reimbursement implications for DTx as well as selection and implementation considerations.

This advisory discusses the epidemiology of the mental health symptoms and conditions of Long COVID, provides evidence-based resources for the treatment of those conditions, and offers possible resources.

This Advisory outlines how healthcare providers (i.e., obstetrician-gynecologists [OB-GYNs], primary care physicians, and other professionals who treat pregnant people) can take an active role in supporting the health of pregnant individuals who have OUD and their babies.

This advisory introduces readers to cannabidiol (CBD), how it is derived, and how it differs from delta-9 THC and other cannabinoids. The advisory focuses on the risks and harms of CBD, especially those sold over the counter. This advisory also clarifies common misconceptions about CBD, given its broad availability and marketing for several medical conditions despite limited evidence of efficacy.

This guide focuses on research supporting adaptations of evidence-based practices (EBPs) for under-resourced populations. Adaptations involve tailoring care, programs, and services to the cultural, social, gender, and demographic contexts of the people served to yield positive outcomes.

This advisory discusses the role of peer support workers and models of peer support services that are available to assist individuals who are experiencing a crisis. Peer support services are a vital component of crisis care.

The Rx Pain Medications, Know the Options, Get the Facts is a series of 13 fact sheets designed to increase awareness of the risks associated with prescription opioid use and misuse, as well as to educate patients who are prescribed opioids for pain about the risks and to provide resources on methods for alternative pain management.

This advisory summarizes data on the use of sublingual and transmucosal buprenorphine as part of medication-assisted treatment (MAT) for opioid use disorder.

Chronic pain is common, multidimensional, and individualized, and treatment can be challenging for healthcare providers as well as patients. In response to the critical need for consistent and current opioid prescribing guidelines, the CDC released the Guideline for Prescribing Opioids for Chronic Pain.

This brief provides guidelines on prescribing Opioids for Pain.

This fact sheet developed by CDC’s National Institute for Occupational Safety and Health (NIOSH) helps employers understand the risk of opioid overdose and allows them to decide if they should establish a workplace naloxone availability and use program.

The American Society of Addiction Medicine (ASAM) developed this pocket guide for healthcare providers which provides instant access to key information in The ASAM Appropriate Use of Testing in Clinical Addiction Medicine in a clear and concise format.

This guide developed by the American Society of Addiction Medicine (ASAM) provides healthcare providers with instant access to current guidelines in a clear concise format.

This pocket guide was produced by the American Society of Addiction Medicine (ASAM) and the National Association of Drug Court Professionals (NADCP) guide.

The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management is intended to aid clinicians in their clinical decision-making and management of patients experiencing alcohol withdrawal syndrome.

This pocket guide was produced by the American Society of Addiction Medicine (ASAM) and the National Association of Drug Court Professionals (NADCP) and is designed to help counselors and therapists working with drug court participants refer and link participants to opioid treatment services in outpatient offices, clinics, and Opioid Treatment Programs (OTPs).